Home › NCT06712459

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Adults aged 18 years or older, regardless of the gender;
2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease);
3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available;
4. Availability of the baseline and follow-up annotations.

Exclusion Criteria:

* None

About the study

Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.

Sponsor: International Extranodal Lymphoma Study Group (IELSG) · Participants: 100 · Started: Oct 13, 2025

Contact the study team

• IELSG Study Coordination Office · Phone: +41 58 666 7321
• Davide Rossi, MD · Phone: +41 91 811 8540

Official record on ClinicalTrials.gov — NCT06712459

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.